Related references
Note: Only part of the references are listed.Maternal embryonic leucine zipper kinase is a novel target for proliferation-associated high-risk myeloma
Arnold Bolomsky et al.
HAEMATOLOGICA (2018)
MELK is a novel therapeutic target in high-risk neuroblastoma
Shan Guan et al.
ONCOTARGET (2018)
Maternal embryonic leucine zipper kinase is a novel target for proliferation-associated high-risk myeloma
Arnold Bolomsky et al.
HAEMATOLOGICA (2018)
Chemotherapy and targeted therapy in the management of cervical cancer
Lalit Kumar et al.
CURRENT PROBLEMS IN CANCER (2018)
MELK expression correlates with tumor mitotic activity but is not required for cancer growth
Christopher J. Giuliano et al.
ELIFE (2018)
Investigational drugs for the treatment of cervical cancer
Fabio Barra et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2017)
MELK: a potential novel therapeutic target for TNBC and other aggressive malignancies
Mary Kathryn Pitner et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2017)
MELK expression in ovarian cancer correlates with poor outcome and its inhibition by OTSSP167 abrogates proliferation and viability of ovarian cancer cells
Reto S. Kohler et al.
GYNECOLOGIC ONCOLOGY (2017)
Antiangiogenics and immunotherapies in cervical cancer: an update and future's view
Daniela Luvero et al.
MEDICAL ONCOLOGY (2017)
MELK and EZH2 Cooperate to Regulate Medulloblastoma Cancer Stem-like Cell Proliferation and Differentiation
Hailong Liu et al.
MOLECULAR CANCER RESEARCH (2017)
p53-independent p21 induction by MELK inhibition
Tatsuo Matsuda et al.
ONCOTARGET (2017)
MELK Promotes Melanoma Growth by Stimulating the NF-κB Pathway
Radoslav Janostiak et al.
CELL REPORTS (2017)
Up-Regulated Maternal Embryonic Leucine Zipper Kinase Predicts Poor Prognosis of Hepatocellular Carcinoma Patients in a Chinese Han Population
Shaohan Wu et al.
MEDICAL SCIENCE MONITOR (2017)
Comparison of survival outcomes between radical hysterectomy and definitive radiochemotherapy in stage IB1 and IIA1 cervical cancer
San-Gang Wu et al.
CANCER MANAGEMENT AND RESEARCH (2017)
MicroRNA-214-3p inhibits proliferation and cell cycle progression by targeting MELK in hepatocellular carcinoma and correlates cancer prognosis
Yue Li et al.
CANCER CELL INTERNATIONAL (2017)
Immunotherapy in ovarian, endometrial and cervical cancer: State of the art and future perspectives
Jole Ventriglia et al.
CANCER TREATMENT REVIEWS (2017)
Chemotherapy and molecular targeting therapy for recurrent cervical cancer
Naotake Tsuda et al.
CHINESE JOURNAL OF CANCER RESEARCH (2016)
Maternal Embryonic Leucine Zipper Kinase (MELK) as a Novel Mediator and Biomarker of Radioresistance in Human Breast Cancer
Corey Speers et al.
CLINICAL CANCER RESEARCH (2016)
Exploiting DNA repair defects for novel cancer therapies
Dik C. van Gent et al.
MOLECULAR BIOLOGY OF THE CELL (2016)
The DNA Damage Response: Implications for Tumor Responses to Radiation and Chemotherapy
Michael Goldstein et al.
ANNUAL REVIEW OF MEDICINE, VOL 66 (2015)
MELK-T1, a small-molecule inhibitor of protein kinase MELK, decreases DNA-damage tolerance in proliferating cancer cells
Lijs Beke et al.
BIOSCIENCE REPORTS (2015)
Global Cancer Statistics, 2012
Lindsey A. Torre et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2015)
DNA Double-Strand Break Repair Inhibitors as Cancer Therapeutics
Mrinal Srivastava et al.
CHEMISTRY & BIOLOGY (2015)
Treatment Advances in Locoregionally Advanced and Stage IVB/Recurrent Cervical Cancer: Can We Agree That More Is Not Always Better?
Kathleen N. Moore et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Development of an orally-administrative MELK-targeting inhibitor that suppresses the growth of various types of human cancer
Suyoun Chung et al.
Oncotarget (2015)
MELK-a conserved kinase: functions, signaling, cancer, and controversy
Ranjit Ganguly et al.
CLINICAL AND TRANSLATIONAL MEDICINE (2015)
Preclinical efficacy of maternal embryonic leucine-zipper kinase (MELK) inhibition in acute myeloid leukemia
Houda Alachkar et al.
ONCOTARGET (2014)
MELK is an oncogenic kinase essential for mitotic progression in basal-like breast cancer cells
Yubao Wang et al.
ELIFE (2014)
Inhibiting the DNA damage response as a therapeutic manoeuvre in cancer
N. J. Curtin
BRITISH JOURNAL OF PHARMACOLOGY (2013)
MELK inhibitor, novel molecular targeted therapeutics for human cancer stem cells
Suyoun Chung et al.
CELL CYCLE (2013)
Maternal Embryonic Leucine Zipper Kinase (MELK): A Novel Regulator in Cell Cycle Control, Embryonic Development, and Cancer
Pengfei Jiang et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2013)
Homologous Recombination as a Replication Fork Escort: Fork-Protection and Recovery
Audrey Costes et al.
BIOMOLECULES (2013)
The DNA damage response and cancer therapy
Christopher J. Lord et al.
NATURE (2012)
Resistance of colorectal cancer cells to radiation and 5-FU is associated with MELK expression
Seungho Choi et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2011)
Identification of copy number gain and overexpressed genes on chromosome arm 20q by an integrative genomic approach in cervical cancer: Potential role in progression
Luigi Scotto et al.
GENES CHROMOSOMES & CANCER (2008)
Gene expression in early stage cervical cancer
Petra Biewenga et al.
GYNECOLOGIC ONCOLOGY (2008)
Gene expression analysis of Preinvasive and invasive cervical squamous cell carcinomas identifies HOXC10 as a key mediator of invasion
Yali Zhai et al.
CANCER RESEARCH (2007)
Share Paper
